Table 1.
Baseline demographics and clinical characteristics
| Parameter | All tirzepatide N = 4,887 | All comparator N = 2,328 | Total N = 7,215 |
|---|---|---|---|
| Age, years | 58.7 (9.9) | 59.0 (10.0) | 58.8 (9.9) |
| Age category, n (%) | |||
| <65 years | 3,421 (68.5) | 1,496 (67.7) | 4,917 (68.1) |
| ≥65 years | 1,466 (31.5) | 832 (32.3) | 2,298 (31.9) |
| Sex, female, n (%) | 2,163 (43.8) | 962 (42.6) | 3,125 (43.3) |
| Ethnicity, n (%) | |||
| Hispanic or Latino | 2,039 (42.3) | 1,020 (42.8) | 3,059 (42.4) |
| Not Hispanic or Latino | 2,212 (45.8) | 1,091 (45.6) | 3,303 (45.8) |
| Not reported | 636 (11.9) | 217 (11.7) | 853 (11.8) |
| Race, n (%) | |||
| American Indian or Alaska Native | 356 (7.4) | 164 (6.7) | 520 (7.2) |
| Asian | 792 (15.1) | 273 (14.1) | 1,065 (14.8) |
| Black or African American | 185 (3.8) | 69 (2.9) | 254 (3.5) |
| Native Hawaiian or Other Pacific Islander or Multiple | 44 (1.0) | 36 (1.3) | 80 (1.1) |
| White | 3,507 (72.6) | 1,783 (75.1) | 5,290 (73.4) |
| Country, n (%) | |||
| United States | 1,084 (21.7) | 503 (22.9) | 1,587 (22.0) |
| Outside United States | 3,803 (78.3) | 1,825 (77.1) | 5,628 (78.0) |
| Weight, kg | 91.12 (20.32) | 90.59 (20.36) | 90.98 (20.37) |
| BMI, kg m−2 | 32.849 (6.263) | 32.673 (6.259) | 32.791 (6.262) |
| Duration of diabetes, years | 9.23 (6.81) | 9.22 (6.78) | 9.26 (6.83) |
| HbA1c, % | 8.30 (0.94) | 8.27 (0.91) | 8.29 (0.93) |
| HbA1c category, n (%) | |||
| ≤8.5% | 3,177 (64.2) | 1475 (64.9) | 4,652 (64.5) |
| >8.5% | 1,709 (35.8) | 853 (35.1) | 2,562 (35.5) |
| Systolic blood pressure, mmHg | 131.88 (14.41) | 132.02 (14.58) | 131.94 (14.49) |
| Diastolic blood pressure, mmHg | 79.22 (9.28) | 79.36 (9.40) | 79.26 (9.34) |
| HDL cholesterol, mg dl−1 | 44.60 (11.81) | 44.86 (11.52) | 44.67 (11.73) |
| LDL cholesterol, mg dl−1 | 93.07 (34.49) | 94.28 (34.85) | 93.45 (34.63) |
| Triglycerides, mg dl−1 | 185.67 (131.72) | 181.61 (134.30) | 184.53 (133.16) |
| Total cholesterol, mg dl−1 | 173.18 (41.76) | 173.90 (42.02) | 173.40 (41.88) |
| Smoking history, yes, n (%) | 1,453 (30.7) | 719 (28.9) | 2,172 (30.1) |
| Current smoking status, yes, n (%) | 822 (16.6) | 416 (18.5) | 1238 (17.2) |
| UACR, mg g−1, median | 11.0 | 12.0 | 12.0 |
| UACR category, n (%) | |||
| Microalbuminuria | 1,156 (24.2) | 560 (23.4) | 1,716 (24.0) |
| Macroalbuminuria | 258 (5.6) | 123 (4.6) | 381 (5.3) |
| eGFR, ml/min/1.73 m2 | 89.02 (18.88) | 88.99 (18.60) | 89.04 (18.76) |
| eGFR category, n (%) | |||
| <60 ml/min/1.73 m2 | 363 (8.4) | 233 (8.2) | 596 (8.3) |
| ≥60 ml/min/1.73 m2 | 4,523 (91.6) | 2,094 (91.8) | 6,617 (91.7) |
Data are presented as mean (s.d.) unless otherwise indicated (mITT population). Percentage is based on the number of participants with non-missing measurement at baseline. Data are strata size adjusted estimate. Strata are defined as trial-level cardiovascular risk (SURPASS-4 forms one stratum, and all other trials form one stratum). eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; N, number of participants in the population; n, number of participants in the specified category; UACR, urine albumin to creatinine ratio.